Editorial
Abstract
This article argues that major risk factors such as diabetes or hypertension increase the risk of vascular disease principally by amplifying the malign interactions of low-density lipoprotein (LDL) particles with the arterial wall and, consequently, that LDL is the first and foremost factor in the pathogenesis of vascular disease. We conclude that marked reduction of the LDL particle number should be the cornerstone of therapy in those with vascular disease or in those at high risk of vascular disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
LDL-C appears to play a pivotal role in atherogenesis, with progressively increasing risk of coronary heart disease with increasing LDL plasma levels.
“LDL-C appears to play a pivotal role in atherogenesis, with progressively increasing risk of coronary heart disease (CHD) with increasing LDL plasma levels [139].”
From Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis (2019) · cites this paper as [139]
Cited by
Sorted by citations
Effects of the amount and intensity of exercise on plasma lipoproteins
Kraus, W. E., Houmard, J. A., Duscha, B. D., Knetzger, K. J., Wharton, M. B., McCartney, J. S., Bales, C. W., Henes, S., Samsa, G. P., Otvos, J. D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020194 · Cited by 1,554 · see citing works
Response of blood lipids to exercise training alone or combined with dietary intervention
LEON, A. S., & SANCHEZ, O. A. (2001) · Medicine and Science in Sports and Exercise · doi:10.1097/00005768-200106001-00021 · Cited by 662 · see citing works
Walldius, G., & Jungner, I. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01276.x · Cited by 395 · see citing works
Olofsson, S. ‐., & Borén, J. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01556.x · Cited by 328 · see citing works
Measurement issues related to lipoprotein heterogeneity
Otvos, J. D., Jeyarajah, E. J., & Cromwell, W. C. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02632-2 · Cited by 259 · see citing works
Slentz, C. A., Houmard, J. A., Johnson, J. L., Bateman, L. A., Tanner, C. J., McCartney, J. S., Duscha, B. D., & Kraus, W. E. (2007) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01314.2006 · Cited by 188 · see citing works
“Research over the last two decades clearly demonstrates that these variables are better indicators of cardiovascular risk than are those measured in the traditional lipid profile (13, 17, 18, 37, 42).”
BackgroundLeon, A. S., Rice, T., Mandel, S., Despres, J.-P., Bergeron, J., Gagnon, J., Rao, D. C., Skinner, J. S., Wilmore, J. H., & Bouchard, C. (2000) · Metabolism · doi:10.1016/s0026-0495(00)80018-9 · Cited by 176 · see citing works
Kite, C., Lahart, I. M., Afzal, I., Broom, D. R., Randeva, H., Kyrou, I., & Brown, J. E. (2019) · Systematic Reviews · doi:10.1186/s13643-019-0962-3 · Cited by 155 · see citing works
Assini, J. M., Mulvihill, E. E., Sutherland, B. G., Telford, D. E., Sawyez, C. G., Felder, S. L., Chhoker, S. S., Edwards, J. Y., Gros, R., & Huff, M. W. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m032631 · Cited by 140 · see citing works
Srinivasan, S. R., Myers, L., & Berenson, G. S. (2002) · PEDIATRICS · doi:10.1542/peds.110.3.e29 · Cited by 138 · see citing works
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias
Sniderman, A. D., Couture, P., & Graaf, J. D. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.50 · Cited by 118 · see citing works
Self-citationDavidson, M. H., Maki, K. C., Marx, P., Maki, A. C., Cyrowski, M. S., Nanavati, N., & Arce, J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3315 · Cited by 107 · see citing works
“Elevated levels of Lp(a) may increase CHD risk by enhancing both thrombogenesis and atherosclerosis.(26,27) The Lp(a) concentration increased modestly (median change of 0.”
BackgroundThe Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity
Kaneva, A. M., Потолицына, Н. Н., Bojko, E. R., & Odland, J. Ø. (2015) · Disease Markers · doi:10.1155/2015/591454 · Cited by 93 · see citing works
Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes
FinnDiane Study Group, Tolonen, N., Forsblom, C. M., Thorn, L. M., Wadén, J., Rosengård‐Bärlund, M., Saraheimo, M., Feodoroff, M., Mäkinen, V., Gordin, D., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1541-2 · Cited by 77 · see citing works
Plasma apolipoproteins and risk for age related maculopathy
Dashti, N. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.093856 · Cited by 66 · see citing works
Rice, T., Després, J.-P., Pérusse, L., Hong, Y., Province, M. A., Bergeron, J., Gagnon, J., Leon, A. S., Skinner, J. S., Wilmore, J. H., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014969.85364.9f · Cited by 65 · see citing works
Apolipoprotein B and Coronary Artery Disease in Women
Westerveld, H. T., van Lennep, J. E. R., van Lennep, H. W. O. R., Liem, A. H., de Boo, J. A. J., van der Schouw, Y. T., & Erkelens, D. W. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.7.1101 · Cited by 61 · see citing works
Upadya, H., Prabhu, S., Prasad, A., Subramanian, D., Gupta, S. B., & Goel, A. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2430-y · Cited by 60 · see citing works
“Lipoprotein cholesterol concentration may not always correspond to lipoprotein concentration [20].”
BackgroundRahmani, M., Raiszadeh, F., Allahverdian, S., Kiaii, S., Navab, M., & Azizi, F. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00715-8 · Cited by 46 · see citing works
Finkelstein, J. M., Heemels, M.-T., Shadan, S., & Weiss, U. K. (2014) · Nature · doi:10.1038/510047a · Cited by 40 · see citing works
Apolipoprotein B as the best predictor of coronary artery disease in Iranian normolipidemic patients
Haidari, M., Moghadam, M., Chinicar, M., Ahmadieh, A., & Doosti, M. (2001) · Clinical Biochemistry · doi:10.1016/s0009-9120(01)00192-8 · Cited by 38 · see citing works
Das, B., Daga, M. K., & Gupta, S. K. (2006) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.08.016 · Cited by 35 · see citing works
Tolonen, N., Forsblom, C. M., Mäkinen, V., Harjutsalo, V., Gordin, D., Feodoroff, M., Sandholm, N., Thorn, L. M., Wadén, J., Taskinen, M., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2873 · Cited by 31 · see citing works
Apolipoprotein B/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients
Zhan, X., Chen, Y., Yan, C., Liu, S., Deng, L., Yang, Y., Qiu, P., Pan, D., Zeng, B., & Chen, Q. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0771-z · Cited by 32 · see citing works
“It is well known that, lipidtransporting apolipoprotein is an essential structural component of the lipoprotein cholesterol [6], VLDL, IDL and LDL cholesterol can each carry only a single apolipoprotein B (apo B) [7] and this characteristic can be used to reliably reflected the number of atherogenic * Correspondence:…”
BackgroundVilla, P., Sagnella, F., Perri, C., Suriano, R., Costantini, B., Macrì, F., Ricciardi, L., & Lanzone, A. (2008) · Climacteric · doi:10.1080/13697130802471058 · Cited by 19 · see citing works
Genetic Markers for Coronary Artery Disease
Veljković, N., Zarić, B. L., Đorić, I., Obradovic, M. M., Sudar-Milovanovic, E. M., Radak, D. J., & Isenović, E. R. (2018) · Medicina · doi:10.3390/medicina54030036 · Cited by 18 · see citing works
“ApoB remains anchored to the lipoproteins without undergoing any changes [37].”
BackgroundRachmani, R., Lidar, M., Brosh, D., et al. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00149-7 · Cited by 18 · see citing works
Nurtazina, A., Kozhakhmetova, D. K., Dautov, D., Shakhanova, A. T., & Chattu, V. K. (2020) · Diagnostics · doi:10.3390/diagnostics10080510 · Cited by 16 · see citing works
“Alongside, transporting molecules like apolipoprotein B (ApoB) are present in all atherogenic types of lipoproteins such as low-density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), and intermediate-density lipoproteins (IDL), and their determination enables a more precise estimat…”
BackgroundPredictive value of apolipoprotein B and A‐I ratio in severe acute pancreatitis
Huh, J. H., Jung, S., Cho, S. K., Lee, K. J., & Kim, J. W. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13860 · Cited by 16 · see citing works
Orloff, D. G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01423-0 · Cited by 15 · see citing works
Relationships of apolipoprotein B100 with the metabolic syndrome in Type 2 diabetes mellitus
Relimpio, F., Losada, F., Pumar, A., Mangas, M. Á., Morales, F., & Astorga, R. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00096-7 · Cited by 14 · see citing works
Gandapur, A. S. K., Manan, M., Nazir, G., Uzma, N., Chawla, J. A., Jadoon, A., & Tauqeer, A. (2006) · PubMed · Cited by 14 · see citing works
Postprandial dyslipidaemia in a nutshell: food for thought
Watts, G. F., Mamo, J. C. L., & Redgrave, T. G. (1998) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1998.tb01560.x · Cited by 14 · see citing works
Nasiri, M., Monazzami, A., alavimilani, S., & Asemi, Z. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01793-0 · Cited by 17 · see citing works
Ethnic differences in low-density lipoprotein particle size in hypertensive adults
Kullo, I. J., Jan, M. F., Bailey, K. R., Mosley, T. H., & Turner, S. T. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.05.001 · Cited by 13 · see citing works
Rossi, A., Baldo-Enzi, G., Ganzaroli, C., et al. (2001) · Journal of Investigative Medicine · doi:10.2310/6650.2001.33627 · Cited by 10 · see citing works
Reference Materials for the Standardization of the Apolipoproteins A-I and B, and Lipoprotein(a).
Dati, F., & Tate, J. R. (2001) · Europe PMC (PubMed Central) · Cited by 10 · see citing works
Comparison of assessment techniques: plasma lipid and lipoproteins related to the metabolic syndrome
Davy, B. M., & Davy, K. P. (2006) · Lipids in Health and Disease · doi:10.1186/1476-511x-5-3 · Cited by 10 · see citing works
Wilson, P. W. F. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.8.1854 · Cited by 9 · see citing works
Changes in serum lipid profile of elite volleyball players in the competition period
Witek, K. (2009) · Biomedical Human Kinetics · doi:10.2478/v10101-009-0016-8 · Cited by 7 · see citing works
Chiong, J. R., & Miller, A. B. (2002) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2002.024 · Cited by 7 · see citing works
“Treatment with an ACE-I, enalapril, substantially reduced LDL oxidation in humans.(26,95,96) Similarly, treatment with an ARB,valsartan, significantly reduced total and LDL cholesterol levels.”
BackgroundKoubaa, N., Nakbi, A., Hammami, S., et al. (2010) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029610369798 · Cited by 7 · see citing works
“biologically plausible,(19,20) because plasma apo B concentrations reflect the number of atherogenic lipoprotein particles.(21) The atherogenic lipoproteins including LDL, and chylomicron remnants contain variable amounts of triglycerides and cholesterol, but each of these particles contain 1 molecule of apo B as stru…”
BackgroundAngelopoulos, T. J., Sivo, S. A., Kyriazis, G. A., Caplan, J. D., Zoeller, R. F., Lowndes, J., Seip, R. L., & Thompson, P. D. (2007) · European Journal of Applied Physiology · doi:10.1007/s00421-007-0537-1 · Cited by 6 · see citing works
“1986) with LDLc being the most robust (Grundy et al. 1985; Pasternak et al. 1996; Sniderman et al. 1997).”
BackgroundMetabolic Impact of Estrogen Replacement Therapy
Villa, P., Moruzzi, M. C., Ap, L., Lanzone, A., & Mancuso, S. (2010) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 4 · see citing works
Nathir, I., Aziz, F. A., & Hashim, R. D. (2023) · Cureus · doi:10.7759/cureus.49854 · Cited by 2 · see citing works
“…of atherogenic lipoproteins including low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), and intermediate-density lipoproteins (IDL), and their determination enables a more accurate estimation of atherogenicity than the traditional lipid biomarkers [5].”
BackgroundLípidos, aterogénesis y riesgo coronario
Evia, B., & Roberto, J. C. A. (2005) · Revista Latinoamericana de Patología Clínica y Medicina de Laboratorio · Cited by 2 · see citing works
Association between Body Iron Stores and Coronary Artery Disease
Nough, H., Sezavar, S. H., Mohebi, A., et al. (2006) · Iranian heart journal · Cited by 1 · see citing works
Apo(B)-dependent dyslipidemic phenotypes in type 1 diabetic patients
Wägner, A. M., Ordóñez‐Llanos, J., Hernández, M., Sánchez‐Quesada, J. L., Blanco‐Vaca, F., Rigla, M., de Leiva, A., & Pérez, A. (2001) · European Journal of Internal Medicine · doi:10.1016/s0953-6205(01)00178-9 · Cited by 1 · see citing works
Lipoproteins and cardiovascular risk
Sniderman, A., Furberg, C. D., van Lennep, J. R., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13566-0 · Cited by 1 · see citing works
Self-citationRahmani, M., Raeiszadeh, F., Verdian, S. A., et al. (2000) · Majallah-i ghudad-i darūn/rīz va mitābulīsm-i Īrān./Majallah-i ghudad-i darūn/rīz va mitābulīsm-i Īrān. · Cited by 1 · see citing works
Nasiri, M., Monazzami, A., alavimilani, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4572348/v1 · Cited by 1 · see citing works
Doe, V. H. (2009) · OhioLink ETD Center (Ohio Library and Information Network)
Koubaa, N., Smaoui, M., Mehri, S., et al. (2011) · InTech eBooks · doi:10.5772/24532
Structure-binding activity relations of amphiphilic polymers and macrophage scavenger receptors
Plourde, N. M. (2010) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t31v5dq9
Moffatt, R. J., & STAMFORD, B. A. (2005) · CRC Press eBooks · doi:10.1201/9781420038422.ch1
The Effect of Cardiac Rehabilitation on 30-Day Hospital Readmission Rates
Shook, A. (2015) · OhioLink ETD Center (Ohio Library and Information Network)
MacKenzie, B. R., Croxson, R. S., & Cumming, G. R. (2000) · Palgrave Macmillan UK eBooks · doi:10.1007/978-1-349-14499-0_21
Nathir, I., Aziz, F. A., & Hashim, R. D. (2025) · PeerJ · doi:10.7717/peerj.19883
“Unlike low density lipoprotein cholesterol (LDL-C), which estimates cholesterol content, apoB directly quantifies the number of atherogenic lipoprotein particles, offering a more precise assessment of atherogenic burden ( Sniderman, Pedersen & Kjekshus, 1997 ).”
- Authors
- Sniderman, A. D., Pedersen, T., & Kjekshus, J.
- Affiliations
- University of Oslo (NO)
- ORCID
- Allan D. Sniderman
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 1997-01
- Volume
- 79
- Issue
- 1
- Pages
- 64-67
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W2421966557
- Cited by
- 57
- References
- 0
- Citations by year
- 2025: 2 · 2023: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 1 · 2015: 2 · 2014: 2 · 2012: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- low-density lipoprotein, LDL particle number, vascular disease, atherogenesis, diabetes mellitus, hypertension, arterial wall, cardiovascular risk factors, lipid-lowering therapy
- MeSH terms
- Apolipoproteins B, Arteriosclerosis, Diabetes Mellitus, Humans, Hypertension, Cholesterol, LDL, Risk Factors, Smoking, Disease Progression, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
